RAPT.Rapt Therapeutics, INC

SCHEDULE 13G/A: Vanguard Group Amends Passive Stake in RAPT Therapeutics, Discloses 2.22% Ownership

Sentiment:

Passive Ownership Disclosure

📋All filings for Rapt Therapeutics, INC
🔒Login to Follow

The Vanguard Group has filed an Amendment No. 3 to its Schedule 13G, reporting a 2.22% beneficial ownership stake in RAPT Therapeutics Inc. as of January 31, 2025.

Summary

  • The Vanguard Group filed an Amendment No. 3 to Schedule 13G concerning its beneficial ownership of Common Stock in RAPT Therapeutics Inc.
  • As of January 31, 2025, The Vanguard Group beneficially owned an aggregate of 2,932,399 shares of RAPT Therapeutics Inc. Common Stock.
  • This ownership represents 2.22% of the total class of securities.
  • The Vanguard Group holds sole dispositive power over 2,908,450 shares and shared dispositive power over 23,949 shares.
  • The firm holds shared voting power over 13,540 shares and no sole voting power.
  • The filing certifies that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of passive institutional ownership and does not contain information to indicate positive or negative sentiment regarding the company's performance or outlook.

Positives

  • The continued presence of a major institutional investor like The Vanguard Group holding a stake, even if passive, indicates standard inclusion in diversified funds and ongoing institutional interest in RAPT Therapeutics Inc.

Future Outlook

This Schedule 13G filing is a disclosure of passive ownership and does not contain any forward-looking statements or guidance regarding RAPT Therapeutics Inc.'s future outlook.

Industry Context

This filing is a routine disclosure of institutional ownership and does not provide specific insights into broader industry trends or competitive positioning for RAPT Therapeutics Inc.

Stakeholder Impact

  • Shareholders: Provides transparency regarding the beneficial ownership stake held by a significant institutional investor, The Vanguard Group.

Key Dates

DateDescription
01/31/2025Date of event which requires filing of this statement (beneficial ownership calculation date).
02/07/2025Date the Schedule 13G Amendment No. 3 was signed.

Keywords

RAPT Therapeutics, Vanguard Group, Schedule 13G, Common Stock, Institutional Ownership, Passive Investment, SEC Filing, Biotechnology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.